• Danielle Jolla, United States says, "I love your online pharmacy Because of your quick shipping and reasonable prices."
  • Jill Barrella, United States says, "Seemed easy to purchase, reasonable prices. Good customer service when I used it."
  • Brian Pavey, United States says, "I am very satisfied with IDM and plan on making more purchases in the future. IDMs prices are low which makes it very compelling to use over conventional pharmacies with high copays and more restrictions continually implemented."
  • Eric Gonzales, United States says, "The website is very user friendly, there is a lot of variety and checking out was easy."
  • Albert Martinez, United States says, "Very organized and efficient concerning delivery and products are great. Very satisfied, impressed with delivery and product."
  • Natalie Wallace, United States says, "I absolutely love getting my medications at a great price and I always get that here. And I recommend this site to my family and friends."
  • Ask our pharmacist, if you have any questions related to your medications
    Click to find International Shipping charges at our pharmacy.
    Shop & Earn @ InternationalDrugMart
    Easy and secure shopping @ InternationalDrugMart.com.
    Get your instant Coupon now!
    Price challenge
    You can find the latest happening of our pharmacy Visit to discuss on various diseases and conditions
    Follow us on Twitter

      Cephalon settles mylan patent matter

      Posted AtThe Street.com

      (CEPH:Nasdaq - commentary - research - Cramer's Take) said Tuesday that it has agreed to settle a patent challenge Mylan Laboratories (MYL:NYSE - commentary - research - Cramer's Take) lodged against the sleep-disorders drug Provigil.


      The deal is Cephalon's thirdsince December with generic-drug makers who have sued to break the Provigil patent in the U.S. Cephalon previously signed similar treaties with India's Ranbaxy Laboratories and Israel's Teva Pharmaceutical Industries (TEVA:Nasdaq ADR - commentary - research - Cramer's Take).

      The agreement with Mylan calls for the companies to stop suing each other. Cephalon will grant Mylan a nonexclusive royalty-bearing right to market and sell generic Provigil in the U.S. starting between October 2011 and April 2012. Mylan could start selling generic Provigil sooner if another company's generic version of the drug reaches the market.

      Still challenging the patent is Barr Pharmaceuticals (BRL:NYSE - commentary - research - Cramer's Take), and the Mylan agreement has no impact on its activities vs. Cephalon.

      Judging from its stock price, investors continue to reward Cephalon for its efforts to settle disputes over its best-selling drug rather than remain tangled in a bunch of lawsuits.

      By midmorning, Cephalon's shares were up $1.56, or 2.2%, to $71.20, on heavier-than-average trading. The stock climbed as high as $71.74, the peak price for the last 52 weeks. Mylan rose 27 cents, or 1.3%, to $21.04.

      In battling the generic-drug companies, Cephalon has argued that the key patent for Provigil remains in force to October 2014 and could run as long as April 2015. Meanwhile, the company has been developing a successor drug, Nuvigil, which is a chemical cousin of Provigil.

      Cephalon had been hoping to get Food and Drug Administration approval for Nuvigil before the possibility of losing a Provigil patent challenge. But if Cephalon makes a deal with Barr, it will have a lot more breathing room and a lot more sales from Provigil, which accounted for $134.5 million, or 43%, of its third-quarter revenue. The FDA is expected to act on Nuvigil by the end of this month.

      January 10, 2006


       

      Share this Article!

    Back to top^